Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Zobrazit další vydání (1)

Multiple myeloma is a B-cell malignancy characterized by the accumulation of plasma cells in the bone marrow and the development of osteolytic bone disease. The present study demonstrates that myeloma cells express the critical osteoclastogenic factor RANKL (the ligand for receptor activator of NF-k...

Podrobná bibliografie
Hlavní autoři:	Croucher, P, Shipman, C, Lippitt, J, Perry, M, Asosingh, K, Hijzen, A, Brabbs, A, van Beek, E, Holen, I, Skerry, T, Dunstan, C, Russell, G, Van Camp, B, Vanderkerken, K
Médium:	Journal article
Jazyk:	English
Vydáno:	2001

Podobné jednotky

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Autor: Croucher, P, a další
Vydáno: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
Autor: Croucher, P, a další
Vydáno: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
Autor: Croucher, P, a další
Vydáno: (2001)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Autor: Croucher, P, a další
Vydáno: (2003)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
Autor: Croucher, P, a další
Vydáno: (2002)

Osteoprotegerin and the development of myeloma bone disease
Autor: Croucher, P, a další
Vydáno: (2004)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
Autor: Shipman, C, a další
Vydáno: (2000)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
Autor: Vanderkerken, K, a další
Vydáno: (2003)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
Autor: Shipman, C, a další
Vydáno: (2002)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
Autor: Shipman, C, a další
Vydáno: (2000)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
Autor: De Leenheer, E, a další
Vydáno: (2004)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
Autor: Shipman, C, a další
Vydáno: (2002)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
Autor: Croucher, P, a další
Vydáno: (2003)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
Autor: Croucher, P, a další
Vydáno: (2002)

Role of osteoprotegerin (OPG) in cancer.
Autor: Holen, I, a další
Vydáno: (2006)

Bisphosphonates--mechanisms of action in multiple myeloma.
Autor: Shipman, C, a další
Vydáno: (2000)

Bisphosphonates and in vivo models of multiple myeloma - Reply
Autor: Shipman, C, a další
Vydáno: (2001)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
Autor: Shipman, C, a další
Vydáno: (2000)

The role of osteoprotegerin in breast and prostate cancer
Autor: Holen, I, a další
Vydáno: (2002)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
Autor: De Leenheer, E, a další
Vydáno: (2002)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
Autor: Shipman, C, a další
Vydáno: (2002)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Autor: Shipman, C, a další
Vydáno: (2003)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
Autor: Holen, I, a další
Vydáno: (2002)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
Autor: Eaton, C, a další
Vydáno: (2004)

RANKL/RANK/osteoprotegerin system as novel therapeutic target in the treatment of primary bone tumors and osteolytic metastases
Autor: Anđelković Zlatibor, a další
Vydáno: (2004-01-01)

Osteocyte CIITA aggravates osteolytic bone lesions in myeloma
Autor: Huan Liu, a další
Vydáno: (2022-06-01)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
Autor: Mueller, G, a další
Vydáno: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
Autor: Mueller, G, a další
Vydáno: (2004)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
Autor: Edwards, C, a další
Vydáno: (2007)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
Autor: Holen, I, a další
Vydáno: (2002)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
Autor: Eaton, C, a další
Vydáno: (2004)

Osteolytic lesions: Multiple myeloma or prostate cancer?
Autor: Akshitha Devaraj, MBBS, a další
Vydáno: (2023-04-01)

Preventing osteolytic lesions and osteomyelitis in multiple myeloma
Autor: Aiken Dao, a další
Vydáno: (2022-12-01)

Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma
Autor: Dongyeop Shin, a další
Vydáno: (2024-01-01)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
Autor: Locklin, R, a další
Vydáno: (2005)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
Autor: Waterman, E, a další
Vydáno: (2007)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Autor: Dongzheng Gai, a další
Vydáno: (2022-09-01)

Multiple myeloma presenting as a massive osteolytic lesion at the clivus
Autor: Domingos Sousa, a další
Vydáno: (2020-11-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
Autor: Dirk Hose, a další
Vydáno: (2024-12-01)

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
Autor: Lwin, S, a další
Vydáno: (2017)